Quest’s First Pooled Sample COVID-19 Diagnostic Test Could Save Time, Resources: FDA

US regulators gave the thumbs-up to the first COVID-19 test that pools patient samples to determine if any one of the individuals in the pool may be infected. Despite concerns such tests may be diluted and make it harder to detect the SARS-CoV-2 virus, the FDA says validation data shows it works.

BROOKLYN, NEW YORK - DECEMBER 13, 2019: QUEST DIAGNOSTICS brand logo sign at location entrance

Over the weekend the US Food and Drug Administration again authorized Quest Diagnostics Incorporated’s Quest SARS-CoV-2 rRT-PCR test, but this time the authorization is to run multiple tests together to see if a patient within a pool of patients has COVID-19. The agency says the new method should save testing resources and help get results faster.

The agency on 18 July announced it gave emergency use authorization (EUA) for the first COVID-19 diagnostics test that can use pooled samples. Such tests allow a group of people...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.